投资者可能会对Inovio提出有关其装置、毒品时限和批准机会的虚假指控,起诉Inovio,导致林业发展局拒绝后股票下降。 Investors may sue Inovio over false claims about its device, drug timeline, and approval chances, causing stock drop after FDA rejection.

在2023年10月10日至2025年12月26日期间购买Inovio制药公司(INO)股票的投资者,可能有资格参加集体诉讼,对据称有关该公司CELLECTRA设备制造的虚假或误导性陈述、该公司INO-3107药品提交时间及其加速批准的前景进行诉讼。 Investors who bought Inovio Pharmaceuticals (INO) stock between October 10, 2023, and December 26, 2025, may be eligible to join a class action lawsuit over alleged false or misleading statements about the company’s CELLECTRA device manufacturing, the timing of its INO-3107 drug’s FDA submission, and its prospects for accelerated approval. 诉讼声称,这些不实陈述夸大了股票价格,在发现真相后造成了损失,包括林业发展局拒绝加速审查后下降24.45%。 The lawsuit claims these misrepresentations inflated the stock price, leading to losses when the truth emerged, including a 24.45% drop after the FDA rejected accelerated review. 2026年4月7日这一最后期限适用于那些寻求成为主要原告的人。 A deadline of April 7, 2026, applies for those seeking to become lead plaintiff. 无需预付任何费用,因为律师在应急基础上工作。 No fees are required upfront, as attorneys work on a contingency basis.